Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:10:56 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:SGMO - SANGAMO THERAPEUTICS INC - https://www.sangamo.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SGMO - Q0.20.4851·0.553.20.4829+0.00160.32,825.71,2372,3260.4826  0.4934  0.473.175  0.3723Jul 17Jun 2415 min RT 2¢

Recent Trades - Last 10 of 2326
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-24 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
2025-05-12 18:26U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
2025-05-12 18:23U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
2025-05-12 16:00U:SGMONews ReleaseSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
2025-05-06 16:35U:SGMONews ReleaseSangamo Therapeutics Announces First Quarter 2025 Earnings Call
2025-05-06 08:30U:SGMONews ReleaseSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
2025-04-28 16:31U:SGMONews ReleaseSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2025-04-03 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
2025-03-17 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2025-03-06 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
2025-02-06 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
2024-12-30 16:15U:SGMONews ReleaseSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec
2024-12-19 02:30U:SGMONews ReleaseSangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
2024-12-19 02:30U:SGMONews ReleaseAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
2024-11-19 16:15U:SGMONews ReleaseSangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
2024-11-12 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
2024-11-04 16:15U:SGMONews ReleaseSangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
2024-10-22 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
2024-08-06 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
2024-08-06 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases